PCT

NurExone’s Intellectual Property Portfolio Expands

Retrieved on: 
Tuesday, February 20, 2024
EVS, EV, Exosome, 3D, NRX, PCT, Cell, B cell, RNA, Patent, 3D bioprinting, IP, Intellectual property, Seminal vesicles, Fine chemical

TORONTO and HAIFA, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, proudly underscores its expanding Intellectual Property (IP) portfolio, which will serve as the foundation for its strategic goal of licensing the innovative ExoTherapy platform to interested biotech companies.

Key Points: 
  • TORONTO and HAIFA, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, proudly underscores its expanding Intellectual Property (IP) portfolio, which will serve as the foundation for its strategic goal of licensing the innovative ExoTherapy platform to interested biotech companies.
  • NurExone’s Intellectual property portfolio describes the ExoTherapy platform’s comprehensive technology and processes for the production of nanodrugs including large scale production of exosomes, loading of active molecules and the composition of the exosomes themselves.
  • The loading technology was presented to the public in the press release of February 12, 2024.
  • Aspects of the company’s platform which relate to Extracellular Vesicles (EVs) production are described in a growing intellectual property portfolio with two PCT applications currently in National Phases.

Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds

Retrieved on: 
Tuesday, February 20, 2024
Therapy, Central nervous system, DMT, LSD, PCT, Patent Cooperation Treaty, Psilocybin, PEA, Patent, CWY, IP, Lysergic acid diethylamide, Research, Pharmaceutical industry

The three patent applications refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of SciSparc' proprietary CannAmide™.

Key Points: 
  • The three patent applications refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of SciSparc' proprietary CannAmide™.
  • "Clearmind continues to be at the forefront of the psychedelic market with one of the largest IP portfolios in the industry.
  • The PCT makes it possible for us to seek patent protection for our proprietary compounds in a large number of countries simultaneously which strengthens our IP portfolio.
  • The latest patent applications build upon Clearmind’s broad IP protection in the psychedelic space, which now includes 27 granted patents and 24 pending patent applications across 15 patent families, nine of which have been granted in major jurisdictions such as the US, Europe, China, and India.

PharmAla Data to be Published in ACS Chemical Neuroscience

Retrieved on: 
Tuesday, February 20, 2024
MDXX, Research, OTC, Drug development, Patent, PCT, International Society, ACS Chemical Neuroscience, MDMA, Safety, University, Drug discovery, ISRP, Medicine, Pharmaceutical industry

It focuses on identifying key targets that are crucial for optimizing the safety and effectiveness of these compounds.

Key Points: 
  • It focuses on identifying key targets that are crucial for optimizing the safety and effectiveness of these compounds.
  • “PharmAla’s drug development program represents some of the world’s best work in the development of novel entactogenic molecules.
  • This research opens new avenues for developing innovative treatments in mental health care,” said Dr. Harpreet Kaur, VP of Research at PharmAla Biotech.
  • “Publication of our PCT filing for the P1 molecule should provide more context and information for potential drug development partners,” said Nick Kadysh, CEO, PharmAla Biotech.

BioVaxys Announces Allowance of DPX-Related Patent for Japan and Filing of Additional International Patent Applications

Retrieved on: 
Tuesday, March 5, 2024
RSV, Cancer, Messenger, Infection, FRA, Patent, APC, PCT, Patent Cooperation Treaty, HSV, Antibody, IMV, Peptide, Antigen, Protein, Intellectual property, Zika virus, Immune system, Vaccine

This Patent was part of the extensive Intellectual Property portfolio recently acquired by BioVaxys from the former IMV, Inc.

Key Points: 
  • This Patent was part of the extensive Intellectual Property portfolio recently acquired by BioVaxys from the former IMV, Inc.
  • This Patent has already been issued in the US, and is currently pending in the EU.
  • BioVaxys also is pleased to announce it filed an international patent application through the Patent Cooperation Treaty ("PCT") from two pending patent applications in the US related to methods of formulating DPX™ compositions that comprise both a lipid-based adjuvant (i.e.
  • The PCT is a patent treaty with more than 150 member countries, makes it possible to seek patent protection for an invention simultaneously in a large number of countries by filing a single "international" patent application instead of filing several separate national or regional patent applications.

Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials

Retrieved on: 
Tuesday, March 5, 2024
AMSilk, A-DNA, AI, Research and development, Molecular biology, PCT, Patent Cooperation Treaty, Protein engineering, Gold, Gel, Microplastics, CO2, BRAIN, Partnership, Fine chemical

The success of this strategic R&D collaboration is based on the use of BRAIN Biotech's rational design in protein engineering.

Key Points: 
  • The success of this strategic R&D collaboration is based on the use of BRAIN Biotech's rational design in protein engineering.
  • BRAIN Biotech had already successfully used its protein engineering strategy in the development of a variety of protein and enzyme products in order to tailor them for industrial applications.
  • Pelzer cites powerful bioinformatics including the various AI approaches used by the experienced protein engineering experts at BRAIN Biotech as the basis for protein engineering, tailoring their approach to each specific inquiry.
  • With their years of protein engineering expertise and with our common vision, BRAIN Biotech is an ideal fit as a development partner."

Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials

Retrieved on: 
Tuesday, March 5, 2024
AMSilk, A-DNA, AI, Research and development, Molecular biology, PCT, Patent Cooperation Treaty, Protein engineering, Gold, Gel, Microplastics, CO2, BRAIN, Partnership, Fine chemical

The success of this strategic R&D collaboration is based on the use of BRAIN Biotech's rational design in protein engineering.

Key Points: 
  • The success of this strategic R&D collaboration is based on the use of BRAIN Biotech's rational design in protein engineering.
  • BRAIN Biotech had already successfully used its protein engineering strategy in the development of a variety of protein and enzyme products in order to tailor them for industrial applications.
  • Pelzer cites powerful bioinformatics including the various AI approaches used by the experienced protein engineering experts at BRAIN Biotech as the basis for protein engineering, tailoring their approach to each specific inquiry.
  • With their years of protein engineering expertise and with our common vision, BRAIN Biotech is an ideal fit as a development partner."

GDToday: 2024 Guangdong 'First Conference of Spring' focuses on promoting high-quality development through industrial science and technology

Retrieved on: 
Tuesday, February 20, 2024
Nieng Yan, Science, PCT, SMART, Conference, GDP, Republic, Spring Festival, Management

GUANGDONG, China, Feb. 20, 2024 /PRNewswire/ -- On February 18, 2024, the first day after the Spring Festival of the Year of Loong in China, Guangdong once again held the "Guangdong Province High-quality Development Conference".

Key Points: 
  • GUANGDONG, China, Feb. 20, 2024 /PRNewswire/ -- On February 18, 2024, the first day after the Spring Festival of the Year of Loong in China, Guangdong once again held the "Guangdong Province High-quality Development Conference".
  • Guangdong's "First Conference of Spring" focuses for two consecutive years on the same theme, which shows the province's emphasis on promoting high-quality development.
  • Its industrial fundaments are solid, making it the largest manufacturing province in the country and an important manufacturing base in the world.
  • In 2024, Guangdong will focus on the theme of high-quality development as industrial science and technology, adhere to the scientific and technological innovation on the enterprise, industry, development, focus on the service manufacturing industry and the real economy, and strive to seize the industrial development opportunities.

NurExone Launches Licensing Efforts for ExoTherapy Platform

Retrieved on: 
Wednesday, February 14, 2024
EVS, Messenger, Plasma protein binding, Exosome, NRX, PCT, Cell, Seminal vesicles, RNA, Patent, Patient, Listeria monocytogenes non-coding RNA, MicroRNA, Carbohydrate, Small RNA, Tissue, Environment, Fine chemical

TORONTO and HAIFA, Israel, Feb. 14, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company, announced today the commencement of efforts to license its proprietary ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes.

Key Points: 
  • TORONTO and HAIFA, Israel, Feb. 14, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company, announced today the commencement of efforts to license its proprietary ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes.
  • The Company’s ExoTherapy platform for exosome-based therapy production includes: (i) large-scale exosome production using the Company’s dedicated bioreactor, (ii) synthesis of therapeutic cargo and (iii) processes to load the therapeutic cargo, creating nanodrugs.
  • Dr. Lior Shaltiel, CEO of NurExone, commented, “Exosomes have the potential to be the ultimate drug delivery system.
  • ExoPTEN, for patients with acute spinal cord injuries, is being developed on our platform, and we expect great success through licensing our technology for other indications!”.

Genflow Biosciences Releases 2023 Year-End Review and Highlights Key Priorities for 2024

Retrieved on: 
Wednesday, February 7, 2024
SIRT6, Fatty liver disease, Investigational New Drug, Research, Therapy, CDMO, Patient, IND, Longevity, EMA, Patent Cooperation Treaty, QMS, Medication, European Medicines Agency, Werner syndrome, NASH, GMP, PCT, Pharmaceutical industry

LONDON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Genflow Biosciences Plc (Genflow or the "Company”) (LSE:GENF) (OTCQB:GENFF), an emerging leader in the field of longevity research developing therapeutics that potentially halt or slow the ageing process is pleased to provide a year-end review and summary of its progress during 2023 and defined strategic priorities for 2024.

Key Points: 
  • LONDON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Genflow Biosciences Plc (Genflow or the "Company”) (LSE:GENF) (OTCQB:GENFF), an emerging leader in the field of longevity research developing therapeutics that potentially halt or slow the ageing process is pleased to provide a year-end review and summary of its progress during 2023 and defined strategic priorities for 2024.
  • Genflow expanded its intellectual property portfolio with a provisional patent application for editing the SIRT6 gene, linked to longevity and age-related diseases.
  • Began trading on the OTCQB Venture Market in the US under the ticker GENFF, aligned to its US-focused strategy.
  • Dr. Eric Leire, CEO of Genflow commented: “The milestones we reached in 2023 were numerous, and I commend our team for their exceptional commitment to execution and delivery.

Genflow Biosciences Releases 2023 Year-End Review and Highlights Key Priorities for 2024

Retrieved on: 
Thursday, February 1, 2024
SIRT6, Fatty liver disease, Investigational New Drug, Research, Therapy, CDMO, Patient, IND, Longevity, EMA, Patent Cooperation Treaty, QMS, Medication, European Medicines Agency, Werner syndrome, NASH, GMP, PCT, Pharmaceutical industry

LONDON, Feb. 01, 2024 (GLOBE NEWSWIRE) -- The Company (LSE:GENF) (OTCQB:GENFF), an emerging leader in the field of longevity research developing therapeutics that potentially halt or slow the ageing process, is pleased to provide a year-end review and summary of its progress during 2023 and defined strategic priorities for 2024.

Key Points: 
  • The full year-end review can be viewed on Genflow’s website: https://genflowbio.com/genflow-biosciences-plc-2023-year-in-review/.
  • Genflow expanded its intellectual property portfolio with a provisional patent application for editing the SIRT6 gene, linked to longevity and age-related diseases.
  • Began trading on the OTCQB Venture Market in the US under the ticker GENFF, aligned to its US-focused strategy.
  • Dr. Eric Leire, CEO of Genflow commented: “The milestones we reached in 2023 were numerous, and I commend our team for their exceptional commitment to execution and delivery.